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Completeness of reporting and risks of overstating impact in 
cluster randomised trials: a systematic review
Elizabeth L Turner, Alyssa C Platt, John A Gallis, Kaitlin Tetreault, Christina Easter, Joanne E McKenzie, Stephen Nash, Andrew B Forbes, 
Karla Hemming, on behalf of the CRT Binary Outcome Reporting Group* 
Overstating the impact of interventions through incomplete or inaccurate reporting can lead to inappropriate scale-up 
of interventions with low impact. Accurate reporting of the impact of interventions is of great importance in global 
health research to protect scarce resources. In global health, the cluster randomised trial design is commonly used to 
evaluate complex, multicomponent interventions, and outcomes are often binary. Complete reporting of impact for 
binary outcomes means reporting both relative and absolute measures. We did a systematic review to assess reporting 
practices and potential to overstate impact in contemporary cluster randomised trials with binary primary outcome. 
We included all reports registered in the Cochrane Central Register of Controlled Trials of two-arm parallel cluster 
randomised trials with at least one binary primary outcome that were published in 2017. Of 73 cluster randomised 
trials, most (60 [82%]) showed incomplete reporting. Of 64 cluster randomised trials for which it was possible to 
evaluate, most (40 [63%]) reported results in such a way that impact could be overstated. Care is needed to report 
complete evidence of impact for the many interventions evaluated using the cluster randomised trial design worldwide. 
Introduction
Well conducted research is important in all settings, 
but particularly so in global health, in which the 
accountability of researchers conducting “public 
health somewhere else” is ever more pressing.1 Well 
conducted randomised trials are required to evaluate 
the community-based, multicomponent, and complex 
interventions that are so often of interest in global 
health research. Such interventions are typically 
evaluated using the cluster randomised trial (CRT) 
design.2 Given the importance of these CRT evaluations 
for decision making regarding the adoption and scale-
up of interventions, it is important that impact be 
correctly estimated by accounting for clustering of 
outcomes and that impact be clearly communicated. 
For the binary outcomes commonly used in CRTs,3 
absolute (eg, risk difference) and relative (eg, risk ratio) 
measures are appropriate and provide complementary 
evidence. The joint use of absolute and relative 
measures has been recommended by the Consolidated 
Standards of Reporting Trials (CONSORT) statement 
on reporting of results of randomised trials, and 
subsequently of CRTs, for nearly two decades.4,5
The rationale for recommending the reporting of both 
absolute and relative effects is well documented.6–8 First, 
there is the potential for large relative effects to mask 
effects that have low public health relevance and, hence, 
for the intervention effect to be overstated. This situation 
arises when outcomes are rare (eg, <10% risk), and no 
accompanying absolute measure is presented.6–8 For 
example, in a CRT of an intervention to promote tobacco 
cessation in India, the reported relative risk of 5∙32 
(95% CI 1∙43–19∙74) and absolute risk difference of 
2∙1 percentage points (95% CI 0∙7–3∙5) was obtained 
from a comparison of cessation proportions of 2∙6% in 
the intervention arm versus 0∙5% in the control arm.9 
Such a magnitude of absolute difference could be 
deemed to be of insufficient public health benefit for the 
intervention to be scaled up, yet had the relative effect 
been reported alone in this rare outcome setting, some 
users of the research findings might have overstated the 
intervention impact. Second, there is the potential for the 
effect of an intervention to be overstated when an odds 
ratio is used as a relative measure of effect. This situation 
arises when outcomes are common (eg, >10% risk) and 
the odds ratio is misinterpreted as a risk ratio.10,11 For 
example, in a CRT of an intervention to link and retain 
adults in HIV care in Eswatini, the reported relative 
risk of 1∙52 (95% CI 1∙19–1∙96) was obtained from a 
comparison of proportions of 64% in the intervention 
arm versus 43% in the control arm.12 If the authors had 
reported an odds ratio in this common outcome setting, 
it would have been approximately 2∙36. Had this figure 
been interpreted as a risk ratio—for example, stating that 
the intervention led to a 136% increase in the proportion 
of study participants linked and retained in HIV care—it 
would be a considerable overstatement of impact given 
that the reported risk ratio estimate showed a relative 
increase of approximately 52%.
It is not yet known how many CRTs adhere to 
guidelines to report both relative and absolute measures, 
and reporting might be worse than for individually 
randomised controlled trials given the additional 
challenges of accounting for clustering in analysis of 
CRTs. A 2020 review showed that only 9% of individually 
randomised controlled trials presented both absolute and 
relative measures.13 Given the importance of CRTs with 
binary outcome for evaluations in real-world contexts,3,14,15 
we did a systematic review of design, analysis, and 
reporting practices of CRTs with binary primary outcome. 
Our goals were to determine the types of measures used, 
the completeness of reporting, and the potential for 
impact to be overstated. Importantly, our investigation 
was not limited by country, context, condition, or type of 
intervention, but instead includes all identified CRTs to 
provide a full picture of global practice.
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Methods
In brief, we included all reports registered in the 
Cochrane Central Register of Controlled Trials of 
two-arm parallel CRTs with at least one binary primary 
outcome that were published between Jan 1 and Dec 31, 
2017. See appendix p 8 for additional details and rationale 
regarding eligibility, including the choice of 2017 and the 
restriction to two-arm parallel designs and to full-scale 
CRTs (ie, no pilot or feasibility CRTs). Data extraction 
was done in duplicate, by random assignment of each 
paper to two of more than 80 participants at three 
different CRT-focused workshops, all of whom were 
experts in statistical methods, and most (66%) of whom 
had experience with CRTs (appendix p 9). Final data 
were agreed by each pair and included consultation with 
lead study authors (ELT or KH), as needed. This strategy 
was adopted to enable the research to be done rapidly to 
high quality but without dedicated funding.16 For more 
details, see the study protocol (appendix pp 25–38) and 
related materials (appendix pp 2–7, 39–50). This 
systematic review is reported in accordance with the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement.17 For the PRISMA 
checklist, see appendix pp 49–50.
We report descriptive characteristics of the included 
studies (eg, study domain, country, and intervention 
type) and the participants doing the data extraction. We 
summarise the proportion of studies reporting absolute 
and relative effects, as well as the proportion of studies 
that reported the primary outcome in such a way that 
there was potential for overstating the magnitude of the 
reported intervention impact. The absolute measures 
were: (1) difference measures (ie, prevalence difference, 
risk difference, or difference in proportions); (2) number 
needed to treat; and (3) other absolute measures. The 
relative measures were: (1) odds ratio; (2) risk ratio, 
relative risk, prevalence ratio, or ratio of proportions; and 
(3) other relative measures. Potential for overstatement 
of impact was defined as either of the following two 
conditions: the outcome was rare (≤10% risk in either 
trial arm) and only a relative measure was reported; or, 
the outcome was common (>10% risk in both arms) and 
the odds ratio was reported (see Introduction for 
examples of each of these situations). The magnitude of 
potential for overstatement of impact through the use of 
odds ratios for common outcomes was quantified via the 
ratio of the odds ratio and the risk ratio. This was 
estimated for each CRT by using the reported risks by 
arm to obtain both the odds ratio and risk ratio, from 
which the ratio of odds ratio to risk ratio was calculated. 
The overall goal of classifying each CRT according to 
whether there is the potential for overstatement is to 
draw attention to how the choice of measures could lead 
to overstatement of impact by users of the research 
findings. Relatedly, in this systematic review, we use 
the term impact to refer specifically to the reported 
effect estimates, and recognise that the true impact is a 
function of implementation, compliance, heterogeneity 
of effects, sustainability over time, and transportability to 
other contexts. 
Results
In brief, after removing duplicates or reports published 
only on a trials registration website, 711 abstracts were 
screened, from which 89 articles were eligible for 
full-text review. Data were extracted by 82 individuals 
(appendix pp 9–10, 21–22) from the 73 articles deter-
mined eligible to be included the systematic review 
(appendix p 23; see appendix pp 51–54 for a full 
reference list). Comparisons of preworkshop inde-
pendent data extraction showed that between-pair inter-
rater agreement on up to 95 distinct variables exceeded 
85% across the 82 individuals involved (appendix p 10), 
with a minimum of 84% at one workshop. Of the 
73 CRTs in the systematic review, the most common 
conditions studied were infectious diseases (19 [26%]) 
and women’s health (16 [22%]; appendix p 11). Close to 
half of the CRTs (35 [48%]) were done in at least one 
country designated as low income or middle income 
(appendix pp 11, 19), with the remainder having all study 
sites in countries designated as high income (38 [52%]).18 
Most CRTs selected a health facility or provider (41 
[56%]) or geographical area (14 [19%]) as the cluster 
(appendix pp 11–12). Finally, most CRTs (46 [65%]) 
studied interventions targeted at participants, namely 
health promotion or educational interventions or 
direct participant therapeutic interventions (appendix 
pp 11–12). Follow-up data were typically collected using 
a questionnaire or survey (34 [47%]) or via electronic 
health records (22 [30%]; appendix p 13). Most CRTs 
(52 [71%]) enrolled fewer than 40 clusters and median 
cluster size was 48 (IQR 20–220; appendix pp 11–12). 
Nine (12%) of the 73 CRTs did not account for clustering 
in analysis (appendix p 15). 37 (77%) of the 48 journals 
in which the articles appeared endorsed the CONSORT 
statement on trial reporting (appendix pp 16–17) and 
58 (79%) of the 73 CRTs appeared in one of those 
journals (appendix p 18).
Of the 73 studies included in the systematic review, 
few (13 [18%]) reported both a relative and absolute 
measure and so, overall, most (60 [82%]) provided an 
incomplete picture of evidence of intervention impact 
(figure 1; appendix p 14). Instead, within the main text of 
each article, most studies (46 [63%]) reported a relative 
measure only, eight (11%) reported an absolute measure 
only, and six (8%) reported no effect measure (typically 
only reporting proportions by arm), with a larger 
number of studies (15 [21%]) reporting no effect measure 
in the abstract. In addition to the six studies reporting no 
effect measure anywhere in the manuscript, three 
articles (4%) did not report outcome proportions by arm 
and therefore only 64 articles could be evaluated for the 
potential to overstate intervention impact (figure 1). Of 
the 59 CRTs (81%) reporting a relative measure, most 
See Online for appendix
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(40 [68%]) reported an odds ratio with fewer (19 [32%]) 
reporting a risk ratio. Of the 21 studies (29%) that 
reported an absolute measure of effect, most (19 [90%]) 
reported a risk difference and three (14%) reported the 
number needed to treat (one of which also reported a 
risk difference)
Of the 64 CRTs reporting an effect measure with 
accompanying risks by arm, most (40 [63%]) were 
classified as having the potential for users of the research 
to overstate intervention impact (figure 1; appendix p 14). 
Potential overstatement was primarily (28 [70%] of 
40 CRTs) because the odds ratio was the chosen relative 
measure for a common outcome (ie, with a reference 
risk >10%). In the remaining 12 CRTs (30%), potential 
overstatement was because only a relative measure (odds 
ratio, risk ratio, or similar) was reported for a rare 
outcome (ie, with a reference risk ≤10%). The magnitude 
of this potential for overstatement is illustrated for 55 of 
the 59 studies that reported a relative measure (figure 2) 
and was quantified via the ratio of the odds ratio and the 
risk ratio: the mean ratio of odds ratio to risk ratio was 
1∙4 (SD 0∙6); median 1·21 (IQR 1∙06–1∙43, range 1–3·2). 
For the 28 CRTs in the common outcome setting that 
reported an odds ratio as the relative measure, the odds 
ratio averaged about 40% larger than the risk ratio and, in 
one case, reached three times the magnitude. Similarly, 
in the rare outcome setting with only a relative effect 
reported, those effects are typically of a large magnitude. 
For example, one CRT had a risk ratio of almost 25 and a 
reference risk of less than 5%. 
Discussion
To prevent inefficient use of scarce resources, there is a 
duty to ensure that results of trials are reported in such a 
way as to allow for a clear and accurate understanding of 
the expected impact of an intervention. Our systematic 
review suggests that few CRTs with binary primary 
outcomes report both an absolute and relative measure of 
effect. As a consequence, most did not present evidence 
in a manner that facilitated accurate interpretation.5 
Figure 1: Summary of reporting of results for CRTs with binary primary outcome
A total of 73 CRTs were included in the systematic review. Percentages above each bar are out of 73, except for the final bar, which is out of 64. Percentages within 
bars have been rounded and therefore might not total 100% (whereas the percentages within the absolute measure bar do not total 100% due to overlap between 
the categories). CRT=cluster randomised trial. NNT=number needed to treat. ROR=ratio of odds ratios. *One article reported proportions per arm with a p value; four 
reported only proportions per arm with neither a p value nor other measure of statistical significance; one reported only a p value with no proportions by arm. †Two 
articles reported difference-in-differences as the between-arm (ie, intervention vs control) difference in the within-arm change in proportion from baseline to 
endline. ‡Two articles reported an ROR: one ROR was a ratio for intervention arm vs control arm of the within-arm odds ratio for baseline to endline change, and one 
ROR was the ratio between two levels of a postrandomisation covariate of the between-arm odds ratio (intervention vs control) of the intervention effect. 
§Categories are not mutually exclusive; one paper reports both an NNT and a risk difference. ¶For the 64 articles that report both an intervention effect as well as 
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Incomplete, and potentially distorted, presentation of the 
evidence has implications for policy and practice, possibly 
leading to the adoption of interventions with smaller than 
perceived impact. Given the widespread use of CRTs in 
the evaluation of interventions in a range of clinical and 
public health settings worldwide, such limitations could 
have far-reaching consequences.
The finding that relative effects are typically reported 
alone might be a consequence of the inherent challenges 
in analysing the clustered binary outcome data that 
often arise in CRTs.11,19 Indeed, as mentioned above, we 
discovered that nine of the 73 CRTs did not account 
for clustering in analysis. Yet, methods are available to 
estimate both risk ratios and risk differences for 
clustered data. These methods include binomial mixed-
effects models or generalised estimating equations, 
with log links (for risk ratios) or identity links (for 
risk differences), or cluster-level methods.11 Relatedly, it 
might be surprising that relative effects were typically 
reported alone given that, as noted above, most of the 
journals in which the articles appeared endorsed the 
CONSORT statement on trial reporting, and most of 
the 73 CRTs appeared in one of those journals. As such, 
responsibility lies with journal editors to promote a shift 
in reporting practices. Likewise, there is a responsibility 
to avoid other poor practices identified in our systematic 
review, including: use of p values in baseline tables; 
ignoring clustering in sample size calculations; and lack 
of clarity about the primary outcome or the primary 
assessment timepoint (appendix p 13).
The finding that the odds ratio is the most commonly 
reported relative effect is probably explained by the fact 
that logistic regression mixed-effects modelling is the 
most well known approach to analysing clustered binary 
outcome data.19 Although odds ratios can be difficult 
to interpret and can lead to overstating of impact, they 
have several advantageous properties. First, although 
the absolute impact of an intervention can differ by 
underlying risk, odds ratios are often stable across 
underlying risk and therefore might be more applicable 
in different populations or different contexts.20 Moreover, 
for outcomes that are very common (eg, risk >80%), the 
odds ratio might be preferred to the risk ratio as a relative 
measure because the risk ratio can mask the magnitude 
of some effects; this is because absolute risk is bounded 
above by 100%.21 Compared with their use in regular 
individually randomised trials, there are additional 
challenges to interpretation of evidence from odds ratios 
in CRTs, because intervention effects estimated by 
mixed models and generalised estimating equations 
using a logit link must be interpreted differently. That is 
to say, odds ratios estimated by use of mixed models 
should be interpreted as cluster-specific effects, whereas 
odds ratios estimated by use of generalised estimating 
equations should be interpre ted as population-averaged 
effects.2,15 The greater the variability between clusters, 
the greater the deviation of the cluster-specific odds ratio 
from the population-averaged odds ratio. By contrast, 
when identity links are used to estimate risk differences 
or log links are used to estimate risk ratios, the 
population-averaged and cluster-specific treatment 
effects are identical.11
Potential limitations of our systematic review 
include methodology and classification of overstate-
ment. Regarding methodology, although we do not 
know how the relatively new crowd-sourcing approach 
would compare with a standard systematic review that 
relies on a few data extractors, the crowd-sourcing 
approach has been previously used by our team to 
evaluate quality of reporting of stepped-wedge designs.16 
To promote high-quality data reporting, data extraction 
(appendix pp 39–48) focused on mostly objective 
measures, data extraction was done in duplicate by 
individuals with statistical expertise (of whom most had 
CRT experience), and all pairs of data extractors were 
able to consult with one of two senior authors during 
in-person workshops for data finalisation. Nevertheless, 
because we leveraged expertise from participants at UK-
based and US-based workshops, few authors would be 
considered experts in global health research done in 
resource-constrained settings. Regarding our classifi-
cation of overstatement, we focused on an objective 
measure of potential overstatement rather than actual 
misinterpretation, which would be very difficult to 
Figure 2: Magnitude of relative effect in relation to reference risk for CRTs with binary primary outcome
55 of the 59 articles reporting relative measures are included in this figure. Four articles cannot be included: two 
articles with a rare outcome (one that reported only a relative measure with an odds ratio of 512, and one that 
reported risk ratios, but only stratified by sex); and two articles with a common outcome which each reported an 
ROR—one ROR was a ratio for intervention arm vs control arm of the within-arm odds ratio for baseline to endline 
change, and one ROR was the ratio between two levels of a postrandomisation covariate of the between-arm odds 
ratio (intervention vs control) of the intervention effect. CRT=cluster randomised trial. ROR=ratio of odds ratios. 
*As shown in figure 1, 40 studies are classified as having the potential for intervention impact to be overstated: 
12 studies reported a relative measure and had a rare outcome (reference risk ≤10%), 11 of which are shown here, 
and 28 studies reported an odds ratio and had a common outcome (reference risk >10%), all of which are shown 
here. †For ease of visualisation, the horizontal axis shows the reference risk, which is the smaller of the reported 
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measure. As such, our estimate of 63% of CRTs 
with potential for overstatement of impact might be 
larger than what actually occurs in practice. In 
other considerations, although we limited ourselves to 
two-arm parallel CRT designs, our findings probably 
extend to more complex designs, including stepped-
wedge, multiarm, and crossover CRTs, as well as to 
observational studies with binary outcomes. Similarly, 
although we have not examined the nature of reporting 
of effects for safety outcomes or of findings from 
subgroup analyses, similar attention should be paid to 
avoid overstating impact in these important domains.
With the increasing move to use evidence generated 
from CRTs to make decisions regarding the adoption 
of interventions in settings around the world, it is 
important that intervention impact be correctly and 
clearly communicated. For the binary outcomes so 
commonly used in decision making, reporting of both 
relative and absolute measures of effect is necessary to 
provide complementary and complete information. 
Many researchers do not realise the importance of 
this fact when communicating their study findings. 
Statisticians face some difficulties in estimating these 
effect measures in CRTs due to the complex nature of 
the models involved, but these difficulties are usually 
surmountable. Journals have a duty to ensure that 
published trials adhere to consensus-based reporting 
guidelines and to ensure that both relative and absolute 
measures are reported. If these issues are not rectified, 
there will undoubtedly be negative consequences on the 
evidence used for decision making about the adoption 
and scale-up of interventions around the world.
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